Antihypertensive agents--the race for third place.
Smith
S A
SA
Littler
W A
WA
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000494:pharmacology; D002216:Captopril / Q000627:therapeutic use; D003981:Diazoxide / Q000627:therapeutic use; D015736:Felodipine; D006801:Humans; D006830:Hydralazine / Q000627:therapeutic use; D007217:Indoramin / Q000627:therapeutic use; D007741:Labetalol / Q000627:therapeutic use; D008914:Minoxidil / Q000627:therapeutic use; D009529:Nicardipine; D009543:Nifedipine / Q000031:analogs & derivatives / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000494:pharmacology; D014700:Verapamil / Q000627:therapeutic use
D000317:Adrenergic alpha-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D014665:Vasodilator Agents; D007217:Indoramin; D006830:Hydralazine; D008914:Minoxidil; D002216:Captopril; D014700:Verapamil; D009529:Nicardipine; D009543:Nifedipine; D003981:Diazoxide; D015736:Felodipine; D007741:Labetalol